Vertex Pharma (VRTX) Tops Q1 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Spain's ex-transport minister sentenced to 24 years for corruption
Vertex Reports First-Quarter 2021 Financial Results
April 29, 2021 4:01 PM EDT-Product revenues of $1.72 billion, a 14% increase compared to Q1 2020-
- Company advancing clinical programs in six additional diseases beyond cystic fibrosis-
-Multiple Phase 2 proof-of-concept study results expected in 2021 -
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2021 and reiterated full-year 2021 guidance for product revenues.
"In CF, our goal is that all eligible patients have access to and can benefit from CFTR modulators. In the first... More
